Joint Formulary & PAD

Quetiapine - Bipolar disorder (adults)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Immediate release tablets
Associated Icons :
Restrictions / Comments :
Important
Preferred

Initiation and stabilisation by a Mental Health specialist for a minimum of 1 month before any request for transfer of prescribing responsibility.

 

Status 2

Red
Formulations :
  • Modified release tablets
Associated Icons :
R
SPC
Restrictions / Comments :
Important

Modified release tablets are reserved for use when immediate release tablets are not suitable.

Modified release quetiapine MAY be continued in Primary Care (after a 3-month period of stabilisation by a Mental Health specialist) where the use of immediate release tablets would risk destabilising the patient.

PAD Profile

ChemicalSubstance :
Quetiapine
Indication :
Bipolar disorder (adults)
Group Name :
Keywords :
mania, bipolar with depression, bipolar with mania
Brand Names Include :
Important Information :

For bipolar with mania / depression.

 

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3
Traffic Light Entries :
2

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the length of prescribing of anti-psychotics by the specialist team at Surrey & Borders Partnership NHS Foundation Trust as:

Mental Health specialist initiation and prescribing for at least 1 month and until the patient is stabilised on treatment prior to transfer of care to primary care.

Where a stabilised patient requires a simple, non-complex and non-urgent dose adjustment, this can be managed in primary care on recommendation by the specialist team.